Fundamental Data for ARRY

ARRAY BIOP(NSDQ:ARRY)

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company''s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

# Employees: 355

Address: 3200 Walnut Street,Boulder,CO,USA

Phone: 303 381-6600

Fax: 303 449-5376

Website: www.arraybiopharma.com

Email: IR@arraybiopharma.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Kyle Lefkoff (Chmn.)

Robert E. Conway (C.E.O.; Dir.)

Michael R. Carruthers (C.F.O.)

Francis J. Bullock Ph.D. (Dir.)

Marvin H. Caruthers Ph.D. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/8/2010

Mean EPS (Next Qtr): ($0.55)

Mean EPS (Year): ($1.99)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 11

Shares Performance

Period	ARRY	Compare to S&P
YTD	-55.06 %	-62.81 %
4 Weeks	1.68 %	-3.48 %
12 Weeks	-37.24 %	-41.56 %

Shares Information

Analyst Coverage: Y

Avg Volume: 255741

Shares Outstanding: 48M

Market Cap: $0.09B

52 Week High: $4.57

52 Week Low: $1.72

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 ARRY split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 5.45 %

EPS Growth in Last Year: 17.46 %

Sales Growth in Last Quarter: 43.27 %

Sales Growth in Last Quarter: 37.27 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 3.230